AU2022273631B2 - Lpa receptor antagonists and uses thereof - Google Patents

Lpa receptor antagonists and uses thereof Download PDF

Info

Publication number
AU2022273631B2
AU2022273631B2 AU2022273631A AU2022273631A AU2022273631B2 AU 2022273631 B2 AU2022273631 B2 AU 2022273631B2 AU 2022273631 A AU2022273631 A AU 2022273631A AU 2022273631 A AU2022273631 A AU 2022273631A AU 2022273631 B2 AU2022273631 B2 AU 2022273631B2
Authority
AU
Australia
Prior art keywords
compound
methyl
mmol
pharmaceutically acceptable
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2022273631A
Other languages
English (en)
Other versions
AU2022273631A1 (en
Inventor
Brian P. BESTVATER
Joshua A. Kaplan
Megan E. NEUBIG
Kin S. YANG
Anna ZAGORSKA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Sciences Inc
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of AU2022273631A1 publication Critical patent/AU2022273631A1/en
Application granted granted Critical
Publication of AU2022273631B2 publication Critical patent/AU2022273631B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2022273631A 2021-05-11 2022-05-10 Lpa receptor antagonists and uses thereof Active AU2022273631B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163186890P 2021-05-11 2021-05-11
US63/186,890 2021-05-11
PCT/US2022/028597 WO2022240879A1 (en) 2021-05-11 2022-05-10 Lpa receptor antagonists and uses thereof

Publications (2)

Publication Number Publication Date
AU2022273631A1 AU2022273631A1 (en) 2023-11-02
AU2022273631B2 true AU2022273631B2 (en) 2025-04-17

Family

ID=81927511

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022273631A Active AU2022273631B2 (en) 2021-05-11 2022-05-10 Lpa receptor antagonists and uses thereof

Country Status (8)

Country Link
US (1) US11980609B2 (enExample)
EP (1) EP4337641A1 (enExample)
JP (1) JP7701473B2 (enExample)
CN (1) CN117295717A (enExample)
AU (1) AU2022273631B2 (enExample)
CA (1) CA3218917A1 (enExample)
TW (2) TWI853704B (enExample)
WO (1) WO2022240879A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114728168B (zh) 2019-11-15 2024-04-09 吉利德科学公司 三唑氨基甲酸酯吡啶基磺酰胺作为lpa受体拮抗剂及其用途
TWI843503B (zh) 2020-06-03 2024-05-21 美商基利科學股份有限公司 Lpa受體拮抗劑及其用途
US11702407B2 (en) 2020-06-03 2023-07-18 Gilead Sciences, Inc. LPA receptor antagonists and uses thereof
KR20240007233A (ko) 2021-05-13 2024-01-16 길리애드 사이언시즈, 인코포레이티드 Lpa 수용체 길항제 및 이의 용도
US11939318B2 (en) 2021-12-08 2024-03-26 Gilead Sciences, Inc. LPA receptor antagonists and uses thereof
WO2024157207A1 (en) * 2023-01-25 2024-08-02 Gpcr Therapeutics, Inc. Gpcr inhibitors and uses thereof
EP4731212A1 (en) * 2023-06-20 2026-04-29 Sagimet Biosciences Inc. Combination therapies of fasn inhibitors with thyroid hormone receptor agonists
JP2026525669A (ja) * 2023-07-28 2026-07-31 武漢朗来科技発展有限公司 Ｌｐａｒ１拮抗剤としての化合物、その医薬組成物および使用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012138648A1 (en) * 2011-04-06 2012-10-11 Irm Llc Compositions and methods for modulating lpa receptors
WO2013189862A1 (en) * 2012-06-20 2013-12-27 F. Hoffmann-La Roche Ag Substituted pyrazole compounds as lpar antagonists
WO2014113485A1 (en) * 2013-01-15 2014-07-24 Intermune, Inc. Lysophosphatidic acid receptor antagonists
WO2019126085A1 (en) * 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Pyrazole n-linked carbamoyl cyclohexyl acids as lpa antagonists
WO2022013378A1 (en) * 2020-07-16 2022-01-20 Chiesi Farmaceutici S.P.A. Amido cyclohexane acid derivatives as lpa receptor inhibitors

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002072576A1 (en) 2001-03-09 2002-09-19 Pfizer Products Inc. Benzimidazole anti-inflammatory compounds
JP4692281B2 (ja) 2003-08-05 2011-06-01 味の素株式会社 新規アゾール化合物
JP4653660B2 (ja) 2003-09-04 2011-03-16 独立行政法人理化学研究所 ＴＧＦ−β活性化制御領域の切断面を認識する抗体
US20070276050A1 (en) 2006-02-27 2007-11-29 Gilead Sciences, Inc. Methods for identifying ASK1 inhibitors useful for preventing and/or treating cardiovascular diseases
AU2009243756B2 (en) 2008-05-05 2013-06-27 Sanofi-Aventis Acylamino-substituted fused cyclopentanecarboxylic acid derivatives and their use as pharmaceuticals
US8455499B2 (en) 2008-12-11 2013-06-04 Amira Pharmaceuticals, Inc. Alkyne antagonists of lysophosphatidic acid receptors
GB2466121B (en) 2008-12-15 2010-12-08 Amira Pharmaceuticals Inc Antagonists of lysophosphatidic acid receptors
GB2470833B (en) 2009-06-03 2011-06-01 Amira Pharmaceuticals Inc Polycyclic antagonists of lysophosphatidic acid receptors
TWI625121B (zh) 2009-07-13 2018-06-01 基利科學股份有限公司 調節細胞凋亡信號之激酶的抑制劑
JP2013501064A (ja) 2009-08-04 2013-01-10 アミラ ファーマシューティカルス，インコーポレーテッド リゾホスファチジン酸受容体アンタゴニストとしての化合物
JP5708936B2 (ja) 2009-09-25 2015-04-30 アステラス製薬株式会社 置換アミド化合物
GB2474748B (en) 2009-10-01 2011-10-12 Amira Pharmaceuticals Inc Polycyclic compounds as lysophosphatidic acid receptor antagonists
GB2474120B (en) 2009-10-01 2011-12-21 Amira Pharmaceuticals Inc Compounds as Lysophosphatidic acid receptor antagonists
AR079022A1 (es) 2009-11-02 2011-12-21 Sanofi Aventis Derivados de acido carboxilico ciclico sustituidos con acilamino, su uso como productos farmaceuticos, composicion farmaceutica y metodo de preparacion
WO2011159550A2 (en) 2010-06-14 2011-12-22 Amidra Pharmaceuticals, Inc. Lysophosphatidic acid receptor antagonist and uses thereof
WO2011159632A1 (en) 2010-06-15 2011-12-22 Amira Pharmaceuticals, Inc. Lysophosphatidic acid receptor antagonists for the treatment of conditions or diseases of the eye
PH12012500542A1 (en) 2010-09-24 2012-11-12 Astellas Pharma Inc Substituted amide compound
CN107721940A (zh) 2010-12-07 2018-02-23 阿米拉制药公司 多环lpa1拮抗剂及其使用
WO2012078593A2 (en) 2010-12-07 2012-06-14 Amira Pharmaceuticals, Inc. Lysophosphatidic acid receptor antagonists and uses thereof
US8785442B2 (en) 2011-01-30 2014-07-22 Curegenix, Inc. Compound as antagonist of lysophosphatidic acid receptor, composition, and use thereof
CN103596947A (zh) 2011-04-05 2014-02-19 艾米拉医药股份有限公司 用于治疗纤维化、疼痛、癌症和呼吸、过敏性、神经系统疾病或心血管疾病的基于3-或5-联苯-4-基异噁唑的化合物
EP2744807A4 (en) 2011-08-15 2015-03-04 Intermune Inc COMPOUNDS AS LYSOPHOSPHIC ACID RECEPTOR ANTAGONISTS
MX370976B (es) 2011-11-11 2020-01-10 Gilead Apollo Llc Inhibidores de acetil coa carboxilasa (acc) y usos de los mismos.
US20140329871A1 (en) 2011-12-04 2014-11-06 Angion Biomedica Corp. Small molecule anti-fibrotic compounds and uses thereof
UY34573A (es) 2012-01-27 2013-06-28 Gilead Sciences Inc Inhibidor de la quinasa que regula la señal de la apoptosis
WO2013134365A1 (en) 2012-03-08 2013-09-12 Ludwig Institute For Cancer Research Ltd TGF-β1 SPECIFIC ANTIBODIES AND METHODS AND USES THEREOF
SG11201407220YA (en) 2012-06-20 2014-12-30 Hoffmann La Roche N-alkyltriazole compounds as lpar antagonists
HK1206339A1 (en) 2012-06-20 2016-01-08 霍夫曼-拉罗奇有限公司 N-aryltriazole compounds as lpar antagonists
BR112015003998A2 (pt) 2012-09-05 2017-07-04 Hoffmann La Roche compostos de cianopirazol lpar-substituídos
US9567310B2 (en) 2012-11-09 2017-02-14 Inserm (Institut National De La Sante Et De La Recharche Medicale) Benzene sulfonamide thiazole compounds
EP2940013B1 (en) 2012-12-28 2018-02-21 Ube Industries, Ltd. Halogen-substituted heterocyclic compound
SG11201507459YA (en) 2013-03-15 2015-10-29 Epigen Biosciences Inc Heterocyclic compounds useful in the treatment of disease
AU2014262638A1 (en) 2013-05-10 2015-11-26 Gilead Apollo, Llc ACC inhibitors and uses thereof
AU2014298373B2 (en) 2013-08-01 2019-12-05 Ludwig Institute For Cancer Research Ltd Anti-GARP protein and uses thereof
GB201314926D0 (en) 2013-08-20 2013-10-02 Takeda Pharmaceutical Novel Compounds
EP3062827A1 (en) 2013-10-31 2016-09-07 Bristol-Myers Squibb Company Radioligands for imaging the lpa-1 receptor
WO2015199234A1 (ja) 2014-06-27 2015-12-30 宇部興産株式会社 ハロゲン置換へテロ環化合物の塩
SG11201705721WA (en) 2015-01-14 2017-08-30 Brigham & Womens Hospital Inc Treatment of cancer with anti-lap monoclonal antibodies
JPWO2017086430A1 (ja) 2015-11-20 2018-09-06 宇部興産株式会社 Ｎａｓｈの治療又は予防のための医薬組成物
CA3155220C (en) 2016-03-02 2024-01-16 Gilead Apollo, Llc Solid forms of a thienopyrimidinedione acc inhibitor and methods for production thereof
AR108185A1 (es) 2016-04-06 2018-07-25 Abbvie Inc Amidas terciarias y método para su uso
AR108838A1 (es) 2016-06-21 2018-10-03 Bristol Myers Squibb Co Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa
CN110382530A (zh) 2017-01-06 2019-10-25 供石公司 亚型特异性、背景许可性TGFβ1抑制剂及其用途
WO2019041340A1 (en) 2017-09-04 2019-03-07 Eli Lilly And Company LYSOPHOSPHATIDE ACID RECEPTOR 1 RECEPTOR INHIBITORS (LPAR1)
WO2019113123A1 (en) 2017-12-04 2019-06-13 Precithera, Inc. TGF-ß RECEPTOR FUSION PROTEINS AND OTHER TGF-ß ANTAGONISTS FOR REDUCING TGF-ß SIGNALING
JP7348899B2 (ja) 2017-12-08 2023-09-21 マレンゴ・セラピューティクス，インコーポレーテッド 多重特異性分子及びその使用
CN111712492B (zh) 2017-12-19 2024-05-31 百时美施贵宝公司 作为lpa拮抗剂的环己基酸三唑唑类
US11447475B2 (en) 2017-12-19 2022-09-20 Bristol-Myers Squibb Company Isoxazole N-linked carbamoyl cyclohexyl acids as LPA antagonists
CA3085561A1 (en) 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Cyclohexyl acid triazole azines as lpa antagonists
JP7369125B2 (ja) 2017-12-19 2023-10-25 ブリストル－マイヤーズ スクイブ カンパニー Ｌｐａアンタゴニストとしてのイソキサゾールｏ－架橋カルバモイルシクロヘキシル酸
JP7212047B2 (ja) 2017-12-19 2023-01-24 ブリストル－マイヤーズ スクイブ カンパニー Ｌｐａアンタゴニストとしてのシクロヘキシル酸ピラゾールアゾール
PE20210655A1 (es) 2017-12-19 2021-03-31 Bristol Myers Squibb Co Carbamoil ciclohexil acidos ligados a n de triazol como antagonistas de lpa
KR102725744B1 (ko) 2017-12-19 2024-11-01 브리스톨-마이어스 스큅 컴퍼니 Lpa 길항제로서의 시클로헥실 산 피라졸 아진
WO2019126087A1 (en) 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Cyclohexyl acid isoxazole azoles as lpa antagonists
US11319309B2 (en) 2017-12-19 2022-05-03 Bristol-Myers Squibb Company Cyclohexyl acid isoxazole azines as LPA antagonists
JP7202383B2 (ja) 2017-12-19 2023-01-11 ブリストル－マイヤーズ スクイブ カンパニー Ｌｐａアンタゴニストとしてのピラゾールｏ－架橋カルバモイルシクロヘキシル酸
KR102800284B1 (ko) 2018-09-18 2025-04-23 브리스톨-마이어스 스큅 컴퍼니 Lpa 길항제로서의 시클로헵틸 산
ES2946657T3 (es) * 2018-09-18 2023-07-24 Bristol Myers Squibb Co Acidos ciclopentílicos como antagonistas de LPA
JP7412424B2 (ja) 2018-09-18 2024-01-12 ブリストル－マイヤーズ スクイブ カンパニー Ｌｐａアンタゴニストとしてのオキサビシクロ酸
AU2019362770B2 (en) 2018-10-15 2025-01-23 Bristol-Myers Squibb Company Radioligands for imaging the LPA1 receptor
US12466804B2 (en) 2019-06-18 2025-11-11 Bristol-Myers Squibb Company Cyclobutyl carboxylic acids as LPA antagonists
EP3986552B1 (en) 2019-06-18 2024-09-18 Bristol-Myers Squibb Company Isoxazole carboxylic acids as lpa antagonists
KR20220024548A (ko) 2019-06-18 2022-03-03 브리스톨-마이어스 스큅 컴퍼니 Lpa 길항제로서의 트리아졸 카르복실산
IL289951B2 (en) 2019-07-30 2025-10-01 Taisho Pharmaceutical Co Ltd Urea compound as an LPA1 receptor antagonist
CN114728168B (zh) 2019-11-15 2024-04-09 吉利德科学公司 三唑氨基甲酸酯吡啶基磺酰胺作为lpa受体拮抗剂及其用途
WO2021110805A1 (en) 2019-12-04 2021-06-10 Idorsia Pharmaceuticals Ltd Combination of an azetidine lpa1 receptor antagonist with pirfenidone and/or nintedanib for use in the treatment of fibrotic diseases
TWI843503B (zh) 2020-06-03 2024-05-21 美商基利科學股份有限公司 Lpa受體拮抗劑及其用途
US11702407B2 (en) 2020-06-03 2023-07-18 Gilead Sciences, Inc. LPA receptor antagonists and uses thereof
IL300525A (en) 2020-08-11 2023-04-01 Viva Star Biosciences Ltd Triazole-pyridinyl-substituted azacyclohexyl acetic acid compounds as LPA receptor antagonists
CN114456147B (zh) 2020-11-10 2025-07-15 武汉人福创新药物研发中心有限公司 氧取代氨基碳酸酯噻吩类化合物
WO2022100623A1 (zh) 2020-11-10 2022-05-19 武汉人福创新药物研发中心有限公司 氮取代杂环噻吩类化合物及其用途
WO2022100625A1 (zh) 2020-11-10 2022-05-19 武汉人福创新药物研发中心有限公司 氮取代氨基碳酸酯噻吩类化合物及其用途
WO2022174882A1 (en) 2021-02-16 2022-08-25 Chiesi Farmaceutici S.P.A. 5-membered heterocyclyl carbamate derivatives as dual lpa receptor 1 and lpa receptor 2 inhibitors
WO2022174883A1 (en) 2021-02-16 2022-08-25 Chiesi Farmaceutici S.P.A. 5-membered heterocyclyl derivatives as dual lpa receptor 1 and lpa receptor 2 inhibitors
KR20240007233A (ko) 2021-05-13 2024-01-16 길리애드 사이언시즈, 인코포레이티드 Lpa 수용체 길항제 및 이의 용도
US11939318B2 (en) 2021-12-08 2024-03-26 Gilead Sciences, Inc. LPA receptor antagonists and uses thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012138648A1 (en) * 2011-04-06 2012-10-11 Irm Llc Compositions and methods for modulating lpa receptors
WO2013189862A1 (en) * 2012-06-20 2013-12-27 F. Hoffmann-La Roche Ag Substituted pyrazole compounds as lpar antagonists
WO2014113485A1 (en) * 2013-01-15 2014-07-24 Intermune, Inc. Lysophosphatidic acid receptor antagonists
WO2019126085A1 (en) * 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Pyrazole n-linked carbamoyl cyclohexyl acids as lpa antagonists
WO2022013378A1 (en) * 2020-07-16 2022-01-20 Chiesi Farmaceutici S.P.A. Amido cyclohexane acid derivatives as lpa receptor inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
QIAN, Y. et al., "Discovery of Highly Selective and Orally Active Lysophosphatidic Acid Receptor-1 Antagonists with Potent Activity on Human Lung Fibroblasts", JOURNAL OF MEDICINAL CHEMISTRY. 2012, vol. 55, pages 7920 - 7939 *

Also Published As

Publication number Publication date
US20220411405A1 (en) 2022-12-29
JP7701473B2 (ja) 2025-07-01
TW202400561A (zh) 2024-01-01
KR20240005892A (ko) 2024-01-12
TW202302537A (zh) 2023-01-16
WO2022240879A1 (en) 2022-11-17
AU2022273631A1 (en) 2023-11-02
US11980609B2 (en) 2024-05-14
EP4337641A1 (en) 2024-03-20
TWI853704B (zh) 2024-08-21
TWI818538B (zh) 2023-10-11
CA3218917A1 (en) 2022-11-17
CN117295717A (zh) 2023-12-26
JP2024517016A (ja) 2024-04-18

Similar Documents

Publication Publication Date Title
AU2021285747B2 (en) LPA receptor antagonists and uses thereof
AU2020384883B2 (en) Triazole carbamate pyridyl sulfonamides as LPA receptor antagonists and uses thereof
AU2022273702B2 (en) Lpa receptor antagonists and uses thereof
JP7701473B2 (ja) Ｌｐａ受容体アンタゴニスト及びそれらの使用
AU2022405082B2 (en) Lpa receptor antagonists and uses thereof
WO2021247215A1 (en) Lpa receptor antagonists and uses thereof
HK40105573A (en) Lpa receptor antagonists and uses thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)